Three Memorial Sloan Kettering faculty members — Paul Meyers, Samuel Singer, and Jedd Wolchok — have been named to endowed chairs.
Three members of Memorial Sloan Kettering’s faculty have been named to endowed chairs. An endowed chair represents one of the highest honors Memorial Sloan Kettering bestows on its most talented faculty.
Paul A. Meyers, Vice Chair for Academic Affairs in the Department of Pediatrics, has been named the incumbent of the newly established Robbins Family Chair in Pediatrics. Dr. Meyers is a pediatric oncologist with extensive experience in the treatment of sarcomas in children and young adults. He directs clinical research aimed at developing and evaluating new therapies and has conducted clinical trials both nationally and at Memorial Sloan Kettering for sarcomas and other unusual tumors that occur in children and young adults. The Robbins Family Chair has been endowed by Clifton S. Robbins and the Robbins Family Foundation.
Surgeon-scientist Samuel Singer has been named to the Vincent Astor Chair of Clinical Research. Dr. Singer is Chief of the Gastric and Mixed Tumor Service in the Department of Surgery and principal investigator of the Memorial Sloan Kettering SPORE in Soft Tissue Sarcoma. In the clinic, he is an expert in the use of combined therapies, such as limb-sparing surgery plus radiation or chemotherapy for soft tissue sarcoma. In the laboratory, his research efforts are focused on a comprehensive integrated molecular, genetic, and biochemical analysis of soft tissue sarcoma to identify new targets for therapy. The chair Dr. Singer holds is part of the Astor family’s long tradition of support to Memorial Sloan Kettering.
Physician-scientist Jedd D. Wolchok has been named to the Lloyd J. Old Chair for Clinical Investigation. Dr. Wolchok is a medical oncologist on the Melanoma and Sarcoma Service with a joint appointment in the Sloan Kettering Institute’s Immunology Program. He is an expert in the treatment of melanoma, the most deadly form of skin cancer. He played a key role in the development of ipilimumab (YervoyTM), a treatment for patients with advanced melanoma. The chair is named for the late Dr. Old, a pioneer in the development of immunotherapy treatments for cancer.